Mr. Quang Pham

Chairman and CEO

Mr. Pham is a biopharmaceutical entrepreneur with over 20 years of experience in founding, financing, and growing companies. Prior to founding Espero, he started Lathian Systems, an innovative company that provided online data and marketing services to pharmaceutical and biotech companies.

As Chairman and CEO, he raised venture capital funding for Lathian, developed products, grew revenues, and led its eventual sale to D&R Communications. Additionally, Quang was President and CEO of Monarch Staffing, a healthcare staffing company in California, and Vice President and General Manager with QTC Management, the largest private provider of government-outsourced disability examinations. Following service as a U.S. Marine Corps aviator, he began his business career in sales roles with Astra-Merck and Genentech. He is a published author and holds a B.A. in Economics from UCLA. Mr. Pham has also received the BioFlorida’s Entrepreneur of the Year Award, named a Veteran of Influence by the Jacksonville Business Journal (JBJ) and recognized as a finalist for the Ernst & Young Entrepreneur Of The Year® 2017 Award. In July, the JBJ named Espero as the fastest growing private company in Northeast Florida. He currently serves on the Board of BioFlorida and is a past director of InHouseUSA, Inc., the Marine Corps Scholarship Foundation and the Chapman University Argyros School Board of Advisors.

Mr. Jeff Cole

President and CFO

Mr. Cole has over 23 years of experience in finance, business development and commercial operations at public and privately held companies. This includes more than 15 years in the pharmaceutical industry holding various senior executive roles at companies such as Valeant Pharmaceuticals (NYSE: VRX), Solco Healthcare US, MarcasUSA, and Legacy Pharmaceuticals. His positions at Valeant included CFO North America, VP of Corporate Development, and General Manager of the US Specialty Division.

During his tenure, Valeant’s revenue in North America increased more than 300%, and while General Manager, Mr. Cole managed a US commercial portfolio of prescription and OTC products across multiple therapeutic areas. As President of Solco Healthcare US, Mr. Cole launched and managed this US commercial pharmaceutical subsidiary of Legacy Pharmaceuticals while serving as the company’s international CFO. Prior to Espero, Mr. Cole founded J. Scott Capital, a firm that provides capital resources to early stage pharmaceutical companies. He also spent six years at PwC Consulting, and served as a principal in the financial management consulting practice. Mr. Cole is a CPA and received his MBA with honors from the University of Michigan. He holds a BS in Accounting from the University of Southern California.

Dr. Pascal Druzgala
Pharm.D., Ph.D.

Senior Vice President,
Research & Development

Dr. Druzgala was a co-founder of Armetheon, where he served as Senior Vice President, Research & Development. He was in charge of all discovery programs. Dr. Druzgala was also a co-founder and board member of Optivia Biotechnology, and a co-founder of ARYx Therapeutics (NASDAQ:ARYX), where he served as senior VP and CSO from 1997 to 2011 as well as chairman of the scientific advisory board.

Dr. Druzgala has a long history of successful pre-clinical drug research and development and is the main author and co-author of more than 40 issued patents in the United States and 150 patents worldwide, including patents covering Armetheon’s clinical drugs.

Dr. Druzgala received a Pharm.D. degree in 1978 from the University of Montpellier, France, and then went on to earn a diplôme d’études approfondies degree (DEA) at the European Institute of Industrial Pharmaceutical Sciences (IPIM), also in Montpellier, France. Dr. Druzgala later graduated in 1985 from the University of Florida with a doctorate in medicinal chemistry. He completed his post-doctorate work at the Center for Drug Design and Discovery at the University of Florida, where he first experimented with various drug discovery programs utilizing retrometabolic techniques. These techniques, pioneered by Dr. Nicholas Bodor in the late 1970s, are the basis for the research into enhanced safety for Espero BioPharma’s clinical-stage drug candidate: tecarfarin.

Mr. Andrew Lam

Vice President, Product Development

Mr. Lam is currently Vice President of Product Development at Espero BioPharma, where he leads the CMC development and pharmaceutical operations.  Prior to joining Espero, Mr. Lam has more than 24 years of experience in pharmaceutical product development, with a primary focus in the development of controlled release products.

Mr. Lam was most recently Vice President of Product Development at Altheos, where he headed the pharmaceutical product development activities and developed novel Rho Kinase Inhibitors products for glaucoma clinical studies. Prior to joining Altheos, Mr. Lam was the Executive Director of Formulation Development at Exelixis, where he advanced numerous discovery compounds in late-stage optimization to first-in-human clinical studies.

Prior to Exelixis, Mr. Lam served as Senior Director of Liquid OROS® Technology Development at ALZA, a Johnson & Johnson company, where he developed the liquid delivery technology for poorly soluble compounds and advanced a number of new molecular entities to human studies. During his tenure at ALZA, Mr. Lam held numerous positions in pharmaceutics research, formulation, process scale-up and development, and served as project team leader for the development of three commercialized products from early compound development to product launch. Andrew received the 2002 Johnson Medal, the most distinguished award at Johnson & Johnson, for development of CONCERTA®, a multi-billion dollar product for attention deficit hyperactive disorder. As pharmaceutical development leader, Mr. Lam filed 29 INDs, 3 NDAs, 2 MAAs and 1 JNDA, and managed the post-approval changes of marketed products.

Andrew is an inventor on 20 issued US patents and 4 additional US published patent applications. He holds a BS in Chemical Engineering from the University of California, Davis.